Plasma Interleukin-6 Predicts Clinical Decline After Completion of Dexamethasone Therapy in Severe COVID-19

To identify and characterize clinical decline after completion of dexamethasone in severe COVID-19 and determine whether interleukin (IL)-6 and other inflammatory biomarkers predict the occurrence of clinical decline. DESIGN: Prospective observational cohort. SETTING: ICUs in three University of Was...

Descripción completa

Detalles Bibliográficos
Autores principales: Mabrey, F. Linzee, Bhatraju, Pavan K., Morrell, Eric D., Zelnick, Leila R., Sathe, Neha A., O’Connor, Nicholas G., Mikacenic, Carmen, Martin, Thomas R., Liles, W. Conrad, Wurfel, Mark M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9760624/
https://www.ncbi.nlm.nih.gov/pubmed/36567786
http://dx.doi.org/10.1097/CCE.0000000000000813

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9760624/
https://www.ncbi.nlm.nih.gov/pubmed/36567786
http://dx.doi.org/10.1097/CCE.0000000000000813

Ejemplares similares